



Delegation Website



BPIPO Website



Your Best Partner in Asia

Booth NO. 1545 & 1645

One-Stop Shop for Taiwan's Biomedical Industry



Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

Room A, 17F, No.3, Park St, Nangang District, Taipei 115, Taiwan

Tel: +886-2-2655-8135

E-Mail: services@biopharm.org.tw

Web: <https://ccd.nat.gov.tw/biopharm/>

BIO International Convention
June 16-19, 2025

Taiwan's Biomedical Excellence: Your Trusted Global Partner!

Environmental characteristics

Taiwan serves as a vital bridge between the EU, U.S., and Asia-Pacific markets, offering a supportive environment for multinational companies. The government actively promotes precision health, fostering collaboration to enhance lifelong well-being by 2030.

With strengths in biomedical research, advanced manufacturing, and regulatory expertise, Taiwan contributes to global healthcare through biopharmaceuticals, medical devices, precision medicine, and digital health. Supported by a strong supply chain and skilled talent, Taiwan's biomedical sector strives to drive meaningful advancements. Partnering with Taiwan means joining a shared effort to shape the future of healthcare.

Strengths and characteristics



Comprehensive Biomedical Clusters

Northern Region

Taipei & Hsinchu

Drugs (Discovery, Biologics, Pharmaceuticals)
Medical Devices (Diagnostics, Medical Electronics, IVD, Medical Imaging)

Central Region

Taichung

Drugs (Pharmaceuticals, Vaccines)
Medical Devices (Rehabilitation Devices, Minimal Invasive Surgical Devices)


Southern Region

Tainan & Kaohsiung


Drugs (API)
Medical Devices (Implantable Devices, Minimal Invasive Surgical Devices)

Pingtung


Herbal Medicines, Functional Foods, Animal Breeding and Vaccines



Booth No.1645



Booth No.1545



CONTENTS

Biologics	Page
ACRO Biomedical Co., Ltd.	01
Ever Supreme Bio Technology	02
Honeybear Biosciences Inc.	03
OBI Pharma, Inc.	04
PharmaEssentia Corp.	05
PrecisemAb Biotech Co., Ltd.	06
Suntec Medical Inc.	07
TrusTrue Bioscience	08

Biotech	Page
Bened Biomedical Co., Ltd.	09
CancerFree Biotech Ltd.	10
Coherence Biotech Co., Ltd.	11
Fluidiconic Biotechnology	12
Health Ever Bio-Tech Co., Ltd.	13
ImmunAdd Inc.	14
Leeuwenhoek Laboratories Co. Ltd.	15
LumiSTAR Biotechnology, Inc.	16
Simpson Biotech	17
TAHO Pharmaceuticals Ltd.	18

TLC BioSciences	19
Xantho Biotechnology Co., Ltd.	20

CDMO	Page
Bora Biologics	21
Mycenax Biotech Inc.	22
SCIWIN Laboratories Co., Ltd.	23
Taiwan Bio-Manufacturing Corporation	24
Taiwan Cell Manufacturing Company	25

Medical Device	Page
BloodScan Biotech Inc.	26
PanCAD.ai Co., Ltd.	27
V-CHECK, Inc.	28

Precision Health	Page
Anivance AI Corporation	29
Instant NanoBiosensors Co., Ltd.	30

CONTENTS

Small Molecule Drug

Energenesis Biomedical Co., Ltd.	31
Lyntonix, Inc.	32
Pharmasaga Co., Ltd.	33
Yoda Therapeutics Inc.	34

Smart Health

Advmeds Co., Ltd.	35
------------------------	----

Non-Profit Institution

Agricultural Technology Research Institute	36
China Productivity Center	37
Development Center for Biotechnology	38
Industrial Technology Research Institute	39
Medical and Pharmaceutical Industry Technology and Development Center	40
National Health Research Institutes	41
Taiwan Bio Industry Organization	42
Taiwan External Trade Development Council	43
Taiwan Stock Exchange	44

Government

Biomedical Translation Research Center, Academia Sinica	45
Biotechnology and Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs	46
Department of Academia-Industry Collaboration and Science Park Affairs, National Science and Technology Council	47
Hsinchu Science Park Bureau, National Science and Technology Council	48
Industrial Development Administration, Ministry of Economic Affairs	49
Ministry of Agriculture	50
Ministry of Health and Welfare	51
National Science and Technology Council	52
Southern Taiwan Science Park Bureau, National Science and Technology Council	53
Startup Island TAIWAN	54
Department of Economic Development, Taipei City Government	55

BIOLOGICS



ACRO Biomedical Co., Ltd.

Business Interests

- Out-Licensing
- Collaborative
- R&D, ODM/OEM
- Distribution

Main Products

- ABCcolla® Collagen Matrix: FDA 510(k)-cleared porous collagen that absorbs exudates and supports moist wound healing.
- ABCcolla® Bone Graft: FDA 510(k)-cleared scaffold for orthopedic and dental bone repair, promoting regeneration and vascularization.
- ABCcolla® Collagen ADM Scaffold: FDA 510(k)-cleared dermal matrix for wound healing, now explored for hair regeneration.
- ABCcolla® Collagen Ophthalmic Matrix: An alternative to human-donated corneas for transplantation.
- ACROTERM™ Scaffolds & Powders: Porcine collagen for stem cell culture, tissue engineering, and 3D bioprinting.

Contact Information

Name:

Ni Wang

Position:

Marketing Specialist

Tel:

+886-7-695-5569 #228

Email:

niwang@acrobiomedical.com



Ever Supreme Bio Technology

Business Interests

- Out-Licensing
- CDMO
- Clinical Trial Collaboration

Main Products / Services / Pipelines & Platforms

- Ever Supreme's CAR001 and INSP003 are innovative cancer therapies. CAR001, a multi-targeting CAR-T therapy, aiming HLA-G and PD-L1, currently enrolling Phase I/IIa trials. INSP003, nano-particle delivering Docetaxel via Fucoidan encapsulation for precise targeting.
- Ever Supreme, a CDMO, offers customized cell & regenerative medicine services across three specialized facilities, supporting clinical & commercial manufacturing while advancing global partnerships for innovative treatments.
- Ever Supreme's four platforms—immune cells, stem cells, nanoparticles, and exosomes—drive innovative therapies for oncology & regenerative medicine, advancing precision treatments for solid tumors & critical diseases.

Contact Information

Name:

Sammi, Hsu

Position:

Director,
Business Development

Tel:

+886-4-2325-2888 #521

Email:

cthsu@ever-supreme.com.tw



Honeybear Biosciences Inc.

Business Interests

- In-Licensing
- Out-Licensing
- Collaborative R&D
- Co-Development
- Strategic Alliance

Contact Information

Name:

Laura Pang

Position:

Administrative Specialist

Tel:

+886-2-2653-0168

Email:

laurapang@honeybearbio.com

Main Services / Pipelines & Platforms

Honeybear Biosciences now offers access to CoNectar®, today's most versatile platform for single- and multiple-payload antibody drug conjugate (ADC) generation. CoNectar® advantages:

- Precise attachment of payloads to optimal site on antibody (Fc)
- Leveraging up to three different enzymatic "handles" on the antibody Fc to create dual payload ADCs with increased efficacy and decreased resistance
- Can dial in precise drug-antibody ratios (DAR) of 2-6.
- No need to change your antibody sequence or expression system; we can use existing drug products, including first generation ADCs
- CMC time and cost savings due to precise enzymatic modification of biochemical handles on antibodies

Honeybear Biosciences, Inc. is a Taiwan-based biotech company with a vision for the global pharmaceutical market. We strive to develop new antibody technologies to bring novel antibody-drug conjugates (ADC) to the patients suffering from devastating cancers.

Honeybear Biosciences has developed a unique site-specific conjugation platform "CoNectar®" and a next generation ADC/ARC product pipeline.



OBI Pharma, Inc.

Business Interests

- Out-Licensing
- Collaborative R&D
- Co-Development
- Strategic Alliance

Contact Information

Name:

Celeste Chuang

Position:

Director,
Business Development

Tel:

+886-2-2655-8799 #217

Email:

cchuang@obipharma.com

Main Services / Pipelines & Platforms

OBI's novel cancer therapeutics:

- Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine)
- OBI-833 (Globo H cancer vaccine)
- OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)
- OBI-992 (TROP2 ADC, cysteine platform)
- OBI-902 (TROP2 ADC, GlycOBI platform)
- OBI-904 (Nectin4 ADC, GlycOBI platform)
- OBI-905 (HER2 ADC, GlycOBI platform)

OBI's proprietary ADC enabling technologies to help customers creating novel and optimized ADCs.

- GlycOBI®
- EndoSymeOBI®
- HyprOBI™
- ThiOBI®

OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (4174.TWO). OBI's mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC enabling technologies and has a novel oncology portfolio listed above.



PharmaEssentia Corp.

Business Interests

- In-Licensing
- Out-Licensing
- Collaborative R&D
- Strategic Alliance

Main Products

Besremi (ropeginterferon alfa-2b)

Contact Information

Name:

KoChung Lin

Position:

CEO

Tel:

+886-2-2655-7688

Email:

kochung_lin@pharmaessentia.com



PrecisemAb Biotech Co., Ltd.

Business Interests

- Out-Licensing
- Collaborative R&D
- Clinical Trial Collaboration
- Co-Development
- Strategic Alliance

Contact Information

Name:

Bingtsung Wu

Position:

Business Development Manager

Tel:

+886-7-311-1577

Email:

bingtsung.wu@precisemab.com

Main Services / Pipelines & Platforms

- Universal Antibody Lock – The GPS for Antibody Drugs Guiding antibody drugs with precision, safety, and market potential.
- The Universal Antibody Lock Technology uses a Hinge + Linker structure to prevent binding to healthy tissues. The Linker, optimized via computational modeling, is specifically cleaved by tumor-associated proteases, ensuring that the antibody remains inactive until it reaches the tumor site. This targeted activation minimizes toxicity while enhancing efficacy.
- PrecisemAb offers Lock technology to partners, providing solutions to improve antibody drug safety.

Key Development Pipelines:

- PSM101 (Lock-EGFR Antibody) has completed efficacy, safety, and process development (titer: 4.2 g/L) and plans IND submission in Q4 2026.
- PSM915 (Lock-TNF α Antibody) demonstrated RA disease inhibition while improving drug safety in preclinical studies.

Validated Products:

- Monoclonal antibody, Bispecific antibody, Antibody-drug conjugate
Lock-anti-PD1, Lock-anti-CTLA-4, Lock-anti-CD28, Lock-anti-CD47,
- Lock-CD3, bispecific Lock-CD3 x CD20, Lock-IL-1 β , and Lock-4-1BB antibodies.



<https://suntecmedical.com/>



Suntec Medical Inc.

Business Interests

- Out-Licensing
- Co-Development
- Investment

Main Pipelines & Platforms

Technology
MINC (Multi-target Immune-modulation Nanocomplex) technology unlocks the brain and penetrates BBB freely to treat Alzheimer's, Parkinson's and Glioma with high efficacy. Strong neuro-regeneration supports its potential to recover patient's cognitive behavior from neuro-degenerative diseases.

Main Products/Pipelines

All three drugs are First-in-class/Best-in-class with potential FDA "Breakthrough Designations" and 18 yr IP protections

- STM-001: For glioma, brain metastatic cancers & 8 solid cancers. In phase I/IIa trials at M.D. Anderson/Johns Hopkins Hospitals. Global market size US \$28B/yr.
- STM-002: Immunotherapy for 40+ cancers. Developed with Dr. T. Honjo (2018 Nobel laureate). At IND enabling stage. Global market size US \$50 B/yr.
- STM-003: For Alzheimer's, Parkinson's and other neurodegenerative diseases. Phase I/IIa in 2026 with Dr. Jeffrey Cummings as PI. Global market size US \$70 B/yr.

Contact Information

Name:

Isaac Cheng

Position:

VP Research

Tel:

+1-9-095-325-825

Email:

isaac.cheng@suntecmedical.com



<https://www.genomics.sinica.edu.tw/en/chen-yun-ru-ruby>



TrusTrue Bioscience

Business Interests

- Out-Licensing
- Co-Development

Main Products / Pipelines & Platforms

This product is a monoclonal antibody targeting misfolded TDP-43 oligomers to treat ALS and TDP-43 proteinopathies, including FTD and AD, without affecting native TDP-43. TDP-43 proteinopathies are present in 95% of ALS, 50% of FTD, and 30–57% of AD cases, all of which lack effective treatments. In ALS mouse models, the antibody improved motor neuron survival, motor behavior, neuromuscular junction reinnervation, reduced TDP-43 oligomer levels, and decreased inflammation. The antibody's humanization is complete, making it a first-in-class therapeutic for ALS.

Indications & Development Stages

- Amyotrophic Lateral Sclerosis (ALS): Currently in preclinical development.
- Frontotemporal Dementia (FTD) & Alzheimer's Disease (AD): Both are in the lead optimization stage.
- Plasma/CSF Biomarker Detection: Undergoing preclinical development.

Contact Information

Name:

Wei-Wei Chang

Position:

Postdoctoral Fellow

Tel:

+886-2-2789-8816

Email:

wwchangym@gmail.com

BIOTECH



<https://www.benedbiomed.com/>



Bened Biomedical Co., Ltd.

Business Interests

- Out-Licensing
- Collaborative R&D
- Clinical Trial Collaboration
- Distribution
- Co-Development
- Strategic Alliance

Main Products / Core Technology

PS128, PS150, and HT-PS23 are patented probiotics that modulate the gut-brain axis.

- PS128 supports neurodevelopmental and neurodegenerative conditions by regulating neurotransmitters and inflammation.
- PS150 reduces anxiety and depression, improves sleep quality and cognitive performance, and enhances the gut microbiota.
- HT-PS23 lowers stress hormone levels, alleviates anxiety, and promotes muscle recovery.

All strains are backed by strong clinical evidence and comprehensive patent portfolios, representing cutting-edge innovation in medical-grade psychobiotics.

Contact Information

Name:

Franklin Cheng

Position:

CEO

Tel:

+886-2-2511-1122

Email:

bened@benedbiomed.com



<https://cancerfree.io/>



CancerFree Biotech Ltd.

Business Interests

- Collaborative R&D
- Distribution
- Co-Development
- Strategic Alliance

Main Products / Services / Pipelines & Platforms

CancerFree Biotech has developed a proprietary cancer cell culture system called E.V.A. (Ex Vivo Avatar). E.V.A. combines 3D cell culture scaffolding with AI image recognition to facilitate tumor cell proliferation. Using just 20mL of patient blood, we can grow tumor cells to generate heterogeneous organoid models that closely mimic the patient's internal tumor. These models allow pharmaceutical companies to identify the best candidates for clinical trials by validating the efficacy of their drugs in suppressing tumor cells from real patients.

Contact Information

Name:

Kevin Chao

Position:

CSO

Tel:

+886-2-2732-2701

Email:

kevin@cancerfree.io



Coherence Biotech Co., Ltd.

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- CRO
- Distribution
- Co-Development
- Strategic Alliance

Main Products / Services

Coherence Bio accelerates AI-driven drug discovery with a programmable, modular benchtop automation system that seamlessly bridges computational models and real-world validation. Our all-in-one platform streamlines complex cell-based assays, cutting iteration times from months to days while eliminating manual workflows, costly in-house automation, and outsourcing delays. Designed for scalability and flexibility, our device enables CROs, biotech, and pharma companies to automate and customize in-vitro testing, accelerating drug development with greater speed, efficiency, and reproducibility.

Contact Information

Name:
Cole Wu
Position:
Co-Founder
Tel:
+886-2-2821-0136
Email:
team@coherencebio.com



Fluidiconic Biotechnology

Business Interests

- Collaborative R&D
- CRO
- Distribution
- Co-Development
- Strategic Alliance

Main Products / Services

- MedSelect:
- Precise drug efficacy evaluations using Tumor-Microenvironment-on-Chip and integrated automation. It combines automated equipment and microfluidic chips as consumables to reconstitute tumor microphysiological systems.
 - Accurately emulating patient-specific tumors by mimicking molecular gradients and dynamic physiological culture.
 - Offering real-time, spatial drug response analysis.
 - Flexible to suit your experimental setup.

- MedSelect:
- Tumor-Microenvironment-on-Chip for precise drug efficacy evaluations.

Contact Information

Name:
Steven Mu
Position:
CEO
Tel:
+886-911-300-283
Email:
slevis185@gmail.com



www.hebiotech.com



Health Ever Bio-Tech Co., Ltd.

Business Interests

- In-Licensing
- Out-Licensing
- Collaborative R&D, CRO
- Clinical Trial Collaboration
- Distribution
- Co-Development
- Strategic Alliance

Main Pipelines & Platforms

- New Drug Product Botreso® for BPH/LUTS. Botreso® is designed to alleviate the symptoms of Benign Prostate Hyperplasia (Known as BPH). The current treatment of BPH / LUTS is mainly based on synthetic drugs, which cause many adverse effects.
- New Drug Product Botreso®, PCP (Prostate Cancer Prevention, IC (Interstitial Cystitis).

Contact Information

Name:

Alex Chen

Position:

Director,
Business Development

Tel:

+886-2-2732-5205 #20

Email:

alex.c@hebiotech.com

ImmunAdd

https://immunadd.com/



ImmunAdd Inc.

Business Interests

- In-Licensing
- Out-Licensing
- Collaborative R&D
- Co-Development

Main Products

IA-05 is a truncated QS-21 analogue with improved tolerability, stability, and long-term immune responses in combination of various antigens. IA-05 is expected to lead novel utilities in development of immunotherapies and therapeutic vaccines.

Contact Information

Name:

Mu-Tzu Chu

Position:

Project Manager

Tel:

+886-939-235-363

Email:

clairechu@immunadd.com



Leeuwenhoek Laboratories Co. Ltd.

Business Interests

- Out-Licensing
- Distributor
- Strategic Alliance

Contact Information

Name:
Chi-Shan Li
Position:
R&D Manager
Tel:
+886-2-2377-2318 #202
Email:
chishan.li@lwhklab.com.tw

Main Products / Services / Pipelines & Platforms

- The product, FLORA LE LIGHT, from Leeuwenhoek Laboratories features a synbiotic formulation exclusively licensed from National Taiwan University. Scientific research has demonstrated that the functional metabolites produced by this formulation can enhance lipid metabolism and clinical studies have shown that FLORA LE LIGHT supports digestive health and modulates the gut environment, leading to an increase in endogenous GLP-1 levels. This mechanism contributes to the overall improvement of metabolic syndrome, offering a scientifically validated approach to metabolic health management.
- Leeuwenhoek Laboratories provides comprehensive metabolomics services to help clients unravel the chemical composition of biological samples. The established metabolomics database can be used to develop artificial intelligence models to predict disease risk and accelerate new drug development. Our services include both targeted and non-targeted metabolite analysis, enabling precise detection and quantification of key metabolic biomarkers.
- Leeuwenhoek Laboratories has isolated 112 Akkermansia muciniphila strains from healthy individuals and established the world's largest A. muciniphila biobank. This biobank comprises 112 bacterial strains, a whole-genome sequence database, a MALDI-TOF mass spectrometry database, and a metabolomics database, providing a powerful resource for research and applications in metabolic disease management. Leveraging this extensive biobank, we have successfully developed a series of AKK strains specifically designed to target metabolic-associated diseases.



LumiSTAR Biotechnology, Inc.

Business Interests

- Out-Licensing
- Collaborative R&D
- Distributor
- CDO and CRO Service

Contact Information

Name:
Min-Wen Chung
Position:
COO
Tel:
+886-966-955-991
Email:
min-wen.chung@lumistar.com.tw

Main Products / Pipelines & Platforms

- iPSC cardiomyocytes
- iPSC neurons
- iPSC microglia cells
- iPSC astrocytes
- LumiRDT live cell imaging reagents

Platform and Service:

- iPSC-based Live Cell Imaging for Drug Screening: Evaluating Compound Efficacy and Toxicity
 - Cardiac Diseases
 - Neurodegenerative Diseases

iPSC Cell Therapy Pipelines:

- Kidney Diseases
- Parkinson's Disease



Simpson Biotech

Business Interests

- ODM
- OEM

Main Products / Services / Pipelines & Platforms

- Health care ingredients made from fermentation or hydrolysis of natural substances
- Fermentation and hydrolysis OEM/ODM
- Recombinant Protein Platform

Contact Information

Name:

Chang-Chih Chen

Position:

Project Manager/ Research Scientist

Tel:

+886-3-396-3466

Email:

bio@simpsonbiotech.com



TAHO Pharmaceuticals Ltd.

Business Interests

- Out-Licensing
- Co-Development
- Strategic Alliance
- CDMO

Main Products / Services / Pipelines & Platforms

- TAHO Pharmaceuticals is dedicated to transforming drug delivery with innovation and care. We create advanced formulations that improve administration, safety, and efficacy of existing drugs—enhancing patients' quality of life. Our lead asset, TAH3311—the first and only oral dissolving film (ODF) for novel oral anticoagulants—is set for FDA/EMA NDA filing. TAH4411, an Ondansetron ODF, is approved in Japan. Other assets include TAH3341 (extended-release Apixaban ODF), TAH2231 (opioid overdose antidote), TAH2211 (addiction therapy), TAH9901 and TAH9922 (ADHD therapies).
- TAHO provides specialized drug delivery solutions through our Transepithelial Delivery System (TDS). We develop transdermal patches and transmucosal films to improve medication administration. Our services include formulation development and partnership support, delivering value and innovation to global pharma collaborators across three continents.
- TAHO's TDS platform drives innovation in transdermal and transmucosal delivery, enhancing lives with compassion. Our diverse pipeline includes:
 - TAH3311: The world's first anticoagulant Apixaban ODF
 - TAH3341: Next generation TAH3311, extended-release Apixaban ODF
 - TAH2231: Naloxone buccal film for opioid overdose
 - TAH4411: Ondansetron ODF for chemo-induced nausea/vomiting
 - TAH2211: Buprenorphine/Naloxone sublingual film for opioid addiction
 - TAH9901: Methylphenidate patch for ADHD
 - TAH9922: Atomoxetine liquid for ADHD

Contact Information

Name:

Paul Chang

Position:

BD Manager

Tel:

+886-2-2659-8515 #2003

Email:

paulchang@tahopharma.com



TLC BioSciences

Business Interests

- Out-Licensing
- Distribution
- Strategic Alliance
- Co-Development

Main Products / Pipelines & Platforms

Ampholipad® (Amphotericin B Liposome for Injection):

- Generic of AmBisome®; commercialized

Proprietary LNP platforms:

- BioSeizer® – Controlled release from days to months, extending therapeutic effects.
- NanoX® – Optimized targeted payload delivery, reducing off-target toxicity.
- Genosphere™ – Enabling disease-modifying RNA-based therapies for osteoarthritis and beyond, opening new frontiers in precision medicine.

Main Pipelines:

- TLC590: Non-opioid extended-release (“ER”) injectable suspension
- TLC599: Non-opioid intra-articular injection for osteoarthritis
- TLC399: ER intra-ocular injection
- TLC178: Orphan drug for rare pediatric cancers.
- TLC501 & TLC502 : Disease-modifying therapies for osteoarthritis.

Contact Information

Name:

Lindsey Yang

Position:

Sr. Associate,
Office Admin & Facilities Management

Tel:

+886-2-2655-7377 #125

Email:

lindsey@tlcbio.com



Xantho Biotechnology Co., Ltd

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- Clinical Trial Collaboration
- Co-Development

Main Products / Pipelines & Platforms

- The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal cream for the treatment of Atopic Dermatitis (AD), plaque psoriasis and wound healing. The efficacy and safety of GM-XANTHO in patients with mild-to-moderate atopic dermatitis have been evaluated in a completed double-blinded, placebo-controlled Phase IIa clinical trial. We are now preparing to advance to a Phase IIb clinical trial.
- GM-XANTHO has obtained IND approvals and completed Phase I/IIa trials in both Taiwan and the United States. It is available for out-licensing, including rights for drug development and commercialization.

Contact Information

Name:

William Liang

Position:

Clinical Project Manager

Tel:

+886-2-2655-7790 #10

Email:

william.liang@xanthobio.com;
business@xanthobio.com

CDMO



Bora Biologics

Business Interests

- CDMO
- Co-Development
- R&D Collaboration
- GMP Manufacturing
- Biologics Development

Main Services

- Biologics Development: Expertise in mAbs, bi-specifics, fusion proteins, recombinant proteins, and enzymes.
- GMP Clinical & Commercial Manufacturing: State-of-the-art facilities with single-use technology (up to 2000L). US FDA-registered for late-stage manufacturing and fill/finish; Taiwan FDA licensed and PIC/S compliant for drug substance.
- Regulatory Compliance: Skilled in navigating regulatory requirements, with 1 FDA-licensed and Health Canada-approved product.
- Development Services: Customized solutions for tech transfer, cell line development, process optimization, analytical services, formulation, and drug product development.

Contact Information

Name:
Rose Chen
Position:
Director,
Business and Program Management
Tel:
+886 3-658-3899 #209
Email:
rose.chen@borabiologics.com



Mycenax Biotech Inc.

Business Interests

- Collaborative R&D
- CDMO
- Co-Development
- Strategic Alliance

Main Services

- CDMO Expertise: 20+ years of development and manufacturing experience in biologics, including mAbs, recombinant proteins, ADCs, and cell & gene therapies.
- Regulatory Compliance: Inspected by EMA, PMDA, and Health Canada, and supported by advanced digital systems including eQMS and LIMS.
- GMP Facilities: 2 plants supporting tox studies, clinical trials, and commercial production with integrated DS & DP services.

Contact Information

Name:
Lin-Lu Tseng
Position:
BD Manager
Tel:
+886-3-667-0880 #5115
Email:
linlu.tseng@mycenax.com



<https://www.sciwinlab.com/>



SCIWIN Laboratories Co., Ltd.

Business Interests

- Collaborative R&D
- CRO
- Co-Development

Main Services

Custom Organic Synthesis Providing CRO & CMO services for API manufacturers and new drug companies

- ADC-Novel linker-Payloads
- Organic synthesis-Small molecule & macromolecule
- Custom synthesis-reference & impurity standard
- Technology transfer-Lab to GMP manufacturer

Contact Information

Name:
CHUNG TSAI WEN
Position:
President
Tel:
+886-2-2298-9116
Email:
carol.chung@sciwinlab.com



<https://tbmcbio.com/>



Taiwan Bio-Manufacturing Corporation

Business Interests

- CDMO
- Strategic Alliance

Main Services

Taiwan Bio-Manufacturing Corporation (TBMC) specializes in CDMO for advanced therapeutics, including mRNA, viral vectors, cell therapies, and biologics. Committed to trust, speed, high quality, flexibility, cost efficiency and expertise, TBMC helps biotech companies transition seamlessly to manufacturing.

Contact Information

Name:
Tsu Hui (Annie) Liu
Position:
Chief Corporate Communications
and Public Affairs
Tel:
+886-2-2653-9898 #8013
Email:
annie.liu@tbmcbio.com



Taiwan Cell Manufacturing Company

Business Interests

- CDMO
- Co-Development
- Strategic Alliance
- Clinical Trial

Main Products / Services

At tcmc, we offer comprehensive CDMO services for advanced cell and gene therapies:

- Viral Vector Production (clinical/commercial):
Cost effective & High-titer LVVs for gene delivery
- Cell Manufacturing (clinical/commercial):
Genetically modified cell (e.g. CAR-T), non-genetically modified cell (e.g. DC, CIK, NK, & stem cells)
- Process Development: Optimized methods for cell & viral vector production
- QC/Regulatory Supporting: CMC packages, Release & Stability Testing

Contact Information

Name:

Sachiko Miyata

Position:

Manager

Tel:

+886-2-8791-1789 #6114

Email:

sachiko.miyata@tcmc.biz

MEDICAL DEVICE



<https://www.bloodscanbiotech.com/>



BloodScan Biotech Inc.

Business Interests

- Out-Licensing
- Collaborative R&D
- CRO
- Distribution
- Strategic Alliance

Contact Information

Name:
Chiping Chang
Position:
Project Manager
Tel:
+886-2-2654-6066
Email:
chiping.chang@
bloodscanbiotech.com

Main Products / Services / Pipelines & Platforms

The Labyrinth One - Automated CTC Enrichment System is a disruptive automated benchtop system designed for the efficient isolation and purification of circulating tumor cells (CTCs) from blood samples.

- Efficient – Purifies CTCs in just 15 minutes
- High Sensitivity – CTC recovery rate exceeds 95%
- Label-Free – Maximizes cell viability for downstream analysis
- User-Friendly – One-touch operation with minimal steps required

The advanced CTC detection services are now available in both the U.S. and Taiwan, providing comprehensive liquid biopsy solutions for cancer research and clinical applications, including:

- CTC Enumeration
- EMT/MET Phenotyping
- Cancer Stem Cell Marker Detection
- CTC Cluster Detection
- Single-Cell Gene Expression Analysis
- Mutation Analysis
- Copy Number Variation (CNV) Analysis
- Protein Expression Profiling
- FISH Analysis

PanCAD.ai

www.pancad.ai



PanCAD.ai Co., Ltd.

Business Interests

- Health Insurance Provider
- Investor
- Distribution
- Healthcare Provider
- Strategic Alliance

Contact Information

Tel:
+886-2-2331-3971
Email:
info@pancad.ai

Main Products

- PANCREASaver: A Novel Computer-Assisted Detection (CAD) Tool for Early Pancreatic Cancer (PC).
- PANCREASaver is an automatic tool determining whether Computed tomography (CT) images harbor PC and indicate tumor location without requiring manual image processing.
- FDA Breakthrough Device
- Taiwan FDA Approved
- US and Taiwan Patented
- Validated by Nationwide Real-World Data
 - Radiology 306(1):172-182, 2023.
 - 2023 RSNA Margulis Award.



<http://vcheck-biomed.com>



V-CHECK, Inc.

Business Interests

- Out-Licensing
- Collaboration for clinical validation
- Distribution Partnership
- Co-Development
- Strategic Alliance

Contact Information

Name:

Vivian Yang

Position:

CEO

Tel:

+886-928-308-180

Email:

vyang@vcheck-biomed.com

Main Products

- V-CHECK specializes in early diagnosis, real-time monitoring, and proactive prevention and treatment of women's diseases. With over 15 years of clinical research and data analysis expertise on women's reproductive medicine, V-CHECK has developed Vido Care Endometriosis ELISA test—an early, cost-effective, and non-invasive solution that also quantitatively tracks the efficacy of hormonal treatments. In addition, our groundbreaking Vido Care Endometriosis LFA is the world's first rapid test designed for decentralized health monitoring, instant diagnosis, and remote referrals. V-CHECK doesn't just accelerate diagnosis—it drives better health outcomes, enhances quality of life, and protects millions of women from preventable harm.
- Biomarker screening, antibody design and immunoassay development.
- Main pipelines: in vitro diagnostic tests for women's reproductive problems.
- Platforms: immunoassay development and manufacturing.

PRECISION HEALTH



Anivance AI Corporation

Business Interests

- In-/Out-Licensing
- Collaborative R&D
- CRO Partnerships
- CDMO Services
- Strategic Partnerships
- Investment & Funding Partnerships

Contact Information

Name:
Guan-Yu Chen Ph.D.
Position:
CEO/ Founder
Tel:
+886-3-573-1920
Email:
guan.chen@anivance.io

Main Services / Pipelines & Platforms

The fastest organ-on-chip platform for new drug development. From design to delivery, we make once-impossible drugs within reach.

Rebuild drug testing from the organ up

- We develop human-relevant models of lung, liver, tumors, and rare diseases.
- Each model is validated and delivered in 1 to 21 days.
- No animals involved.

Decode biology at scale with AI-powered imaging

- Cell Painting and high-throughput workflows extract phenotypic fingerprints.
- AI accelerates interpretation across complex conditions.
- Results within hours.

Your virtual experiment assistant, powered by multi-agent AI

- It designs, simulates, analyzes and reports in minutes.
- Fully integrated into our organ-on-chip system to support rapid decisions.



Instant NanoBiosensors Co., Ltd

Business Interests

- Out-Licensing
- Collaborative R&D
- CRO
- ODM / OEM
- Clinical Trial Collaboration
- Distribution
- Co-Development
- Strategic Alliance

Contact Information

Name:
SURI HUANG
Position:
Marketing Director
Tel:
+886-2-2653-8655
Email:
cmo@instantnano.com

Main Products / Services / Pipelines & Platforms

- **Alzheimer's Ultra-Sensitive Blood Test Platform**
The only POCT solution integrating antibody analysis to assay development, suitable for the detection of low-concentration protein biomarkers. In addition, by streamlining the complexity of conventional blood-based biomarker diagnostics, our platform delivers accessible and highly accurate solutions for early detection and continuous therapeutic monitoring.

- **Leukemia Embedded Precision Medicine NGS Solution**
Fully integrated NGS platform covers the entire workflow—from sample processing to final report generation. Our offerings include instruments for Automated Nucleic Acid Purification Platform, NGS Library Preparation Workstation as well as the Leukemia reagent panel and integrated analysis software. This solution is highly cost-effective and competitive.

---Key Advantages---

1. DimerOff™ Technology – Reduces sequencing noise for cleaner, more accurate data.
2. Fast & Affordable – 50% lower cost with results in just 3 days.
3. MRD & MPN Monitoring – Enables precise disease tracking.
4. Custom Panels – Flexible, cost-effective designs for clinical and research use.

SMALL MOLECULE DRUG



Energenesis Biomedical Co., Ltd.

Business Interests

- Out-Licensing
- Distribution
- Co-Development
- Strategic Alliance

Main Pipelines & Platforms

Energenesis is focused on developing innovative therapeutics based on its proprietary ENERGI-Platform, which uses small molecule drugs to increase cellular energy (ATP) levels and activate self-healing mechanisms. Main pipelines:

- ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase III)
- ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD&RPD)
- ENERGI-F705PD: oral medicine for Parkinson's disease (in preparation for Phase II)
- ENERGI-F701: hair tonic for Alopecia (Phase II)

Contact Information

Name:

Shelly Yang

Position:

BD Manager

Tel:

+886-2-2627-0835 #803

Email:

shelly@energenesis-biomedical.com



LYNTONIX, INC.

Business Interests

- Co-Development
- Fundraising
- Out-Licensing

Main Products

- LTX-568, a first-in-class drug for abdominal pain in irritable bowel syndrome (IBS)
- Demonstrate potent and long-lasting analgesic effect for IBS visceral pain after oral administration
- Exhibit high safety and therapeutic index
- Seeking co-development and/or fundraising opportunities to conduct IND-enabling preclinical GLP studies

Contact Information

Name:

Jack Hsin

Position:

CEO

Tel:

+886-919-381-624

Email:

xin@lyntonix.com



<https://www.pharmasaga.com/en/index.aspx>



Pharmasaga Co., Ltd.

Business Interests

- Out-Licensing
- Clinical Trial Collaboration
- Co-Development

Main Services

Pharmasaga is a clinical drug development company dedicated to development of novel anti-diabetic drugs. PS1, a Pdia4-based small-molecule drug candidate, can treat and reverse diabetes. Pharmasaga has clinical assets and a drug screening platform as described below. Both assets and platform are intended for out-licensing to pharmaceutical companies.

- PS1 for type 2 diabetes.
- PS1 for type 1 diabetes.
- PS1 is for diabetes of pets.
- A platform to screen drugs.

Contact Information

Name:

Yi-San Lee

Position:

COO

Tel:

+886-908-688-896

Email:

coo@pharmasaga.com



<https://yodapharma.com/#/>



Yoda Therapeutics Inc.

Business Interests

- Clinical Trial Collaboration
- Out-Licensing
- Co-Development
- Future Co-Promotion
- Fund Raising

Main Products

Yoda Therapeutics Inc. is an AI-driven company that focuses on drug development for central nervous system (CNS) disorders. Our mission is to address unmet medical needs by offering innovative treatment options. Our flagship drug, YA-101, is an AI-modeled New Chemical Entity specifically designed to treat Multiple System Atrophy (MSA). YA-101 has shown significant therapeutic potential in animal studies and demonstrated a favorable safety profile in a Phase I trial involving healthy adults. In 2022, it received Orphan Drug Designation (ODD) from the U.S. FDA for MSA. YA-101 is currently undergoing Phase II trials in both the U.S. and Taiwan.

Contact Information

Name:

Da-Zhong Luo

Position:

Non-Clinical R&D Director

Tel:

+886-952-730-761

Email:

dzluo@yodapharma.com

**SMART
HEALTH**



Advmeds Co., Ltd.

Business Interests

- Out-Licensing
- Co-Development

Contact Information

Name:
Johnson Huang
Position:
Managing Director
Tel:
+886-935-681-563
Email:
johnson@advmeds.com

Main Pipelines & Platforms

- Docloop.AI
- Next-Generation AI Remote Care Platform
Docloop.AI is the first to leverage generative AI in a "speech-to-care" approach to expand and streamline healthcare solutions. By integrating vast health data with AI-driven analysis of medical history, lifestyle, and environmental factors, we enhance health management and address workforce shortages.
 - Our platform connects over 150 types of devices, linking clinical data, home devices, and mobile apps. We also provide digital tools such as questionnaires, telemedicine, and more than 22 modular tools, including over 50 care service scripts for cancer screening, dementia support, and post-surgery care. With over a million users and widespread adoption, Docloop.AI is building the foundation for intelligent healthcare.

NON-PROFIT INSTITUTION



<http://www.atri.org.tw>



Agricultural Technology Research Institute

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- CRO

Contact Information

Name:
Chun-Hsiang, Hou
Position:
Associate Researcher
Tel:
+886-37-585-774
Email:
1052031@mail.atri.org.tw

Main Services / Pipelines & Platforms

- Animal Study
- Certification: OECD-GLP and AAALAC
 - Efficacy: Acute myocardial ischemia (AMI), Wound healing, Dental defect, Pulmonary fibrosis study, and Customized animal models
 - Safety testing: Skin toxicity testing, Medical devices biocompatibility
- Biosafety Testing Services
- Certification: OECD-GLP, TFDA-GLP, and PIC/S GMP
 - Service: Biological Safety Testing and Virus Validation
- SPF Pig Tissue Supply
- Tissues: SPF pig skin and bone
 - Certification: ISO 13485:2016 according to ISO 22442-1:2015 and ISO 22442-2:2015
 - Application: Production of collagen and bone meal
- Animal vaccine safety and efficacy test
- Swine challenge model: PRRSV, PCV2, CSF, APP, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis.
 - Poultry challenge model: ND (Newcastle disease), MD (Marek's disease), Mycoplasma gallisepticum, Mycoplasma synoviae.
 - Others: customized animal challenge model
- Antimicrobial susceptibility test
- Certification: ISO/IEC 17025



<https://www.cpc.org.tw/en-us>



China Productivity Center

Business Interests

- Seeking in-/out-licensing, collaborative R&D, CDMO opportunities for Taiwanese biotechnology and medicine companies.

Contact Information

Name:
Sherry Shang
Position:
Manager
Tel:
+886-2-2698-2989 #01954
Email:
01954@cpc.org.tw

Main Services / Pipelines & Platforms

China Productivity Center(CPC), as the executive organizer of the 2025 Taipei City Biotechnology Industry Guidance Program. We are honored to have this opportunity to gather around outstanding biotech and medical companies for Taipei City Government to participate in the world's largest event for the biotechnology industry. By showcasing their latest products and R&D activities at the event, it is our mutual goal to elevate the visibility and discover new opportunities.

Our core business scope:

- Management Consulting
- Government Projects
- Education and Training
- Media Publication
- International Exchange
- Management Knowledge Center



Development Center for Biotechnology

Business Interests

- In-Licensing
- Out-Licensing
- Collaborative R&D
- CDMO
- CRO
- Co-Development
- Strategic Alliance

Contact Information

Name:
Ching-Hsu Yang
Position:
Research Fellow
Tel:
+886-2-7700-3800 #5293
Email:
ch.yang@dcb.org.tw

Main Pipelines & Platforms

- Biologics
- PD-L1 mAb
 - CSF-1R mAb
 - Globo H/IO CAR-T (DCBGM2302) / Gastric Cancer
 - NTSR1 ADC (DCBAD2301) / Head and Neck Cancer
 - B7-H3 ADC (DCBAD2303) / B7-H3-positive Tumors
- Pharmaceutics
- Raf Inhibitor / Melanoma
 - FPR1 Antagonist / Neutrophil Related Inflammatory Diseases
 - TXNDC5 Oligonucleotide Drug / Idiopathic Pulmonary Fibrosis
- Platforms
- Human Synthetic Antibody Library for Therapeutic Drug Discovery
 - The High Yield Therapeutic mRNA Production Platform
 - Oligonucleotide Delivery Platform: Novel Sequential GalNAc Linker



Industrial Technology Research Institute

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- Clinical Trial Collaboration
- Co-Development
- Strategic Alliance

Contact Information

Name:
Sing Lin
Position:
Administrator
Tel:
+886-3-582-0100
Email:
ITRI_BDL@itri.org.tw

Main Services / Pipelines & Platforms

- Next-Gen Drug Discovery Platform
- Generative AI for Drug Discovery
 - In Vivo CAR-M mRNA-LNP Therapy for Solid Tumors
 - Eye Drop Formulation for the Dry Age-Related Macular Degeneration
- Leading Exosome Application Platform
- iPSC, iMSC Derived Exosome
 - Enrichment and Detection of Exosomes
 - Exosome Production Chip for Nucleic Acid Delivery
- ITRI's one-stop biomedical services:
- R&D/ Prototyping
 - Technology Licensing
 - Preclinical/Clinical Trial
 - GXP trial production
 - Regulation Consulting



Medical and Pharmaceutical Industry Technology and Development Center

Business Interests

- CDMO
- Co-Development
- Tech-transfer of pharmaceutical products
- Medical devices, botanical products and stem cell therapy products

Contact Information

Tel:
+886-2-6625-1166
Email:
pitdc_p@pitdc.org.tw

Main Pipelines & Platforms

- Pharma 4.0-Continuous manufacturing
- Insoluble drug technique
 - Hot-melt extrusion drug manufacturing technology
 - Spray-dried technology
 - Nanocrystal
 - Solvent evaporation
- Long-acting injectables
 - Hot-melt extrusion-implant
 - Nanocrystal
 - Type 4/7 dissolution apparatus
- Lipid nanoparticle(LNP)
 - Microfluid
 - Nanosizer
 - GalNAc-Hepatocyte targeting
- Drug eluting medical devices
- Botanical product development (Small molecule drugs, Functional food)
- Stem cell pipeline for fibrosis
- Cell culture medium optimization



National Health Research Institutes

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- Clinical Trial Collaboration
- Co-Development
- Strategic Alliance

Contact Information

Name:
Liang, Hua-Hsuan
Position:
Acting Section Chief
Tel:
+886-37-206166 #33206
Email:
huahsuan@nhri.edu.tw

Main Products / Services

- advance biomedical sciences
- promote population and individual health
- forge biotechnology and pharmaceutical development
- train and cultivate biomedical researchers
- Value-Added MedChem Innovation Center (VMIC)
- Lead Compound and Developmental Drug Candidate Evaluation Services Core Facilities
- One-stop early drug discovery/preclinical services platform
- IBEN-Service Information
- Taiwan Zebrafish Core Facility @ NHRI
- National Health Research Institutes Biobank
- Core Instrument Center
- Nucleic acid drugs and raw materials service platform
- National Infectious Diseases Bank



<https://taiwanbio.org.tw/en/>



Taiwan Bio Industry Organization

Business Interests

- Strategic Alliance
- BIO Asia–Taiwan International Conference and Exhibition
- Taiwan CDMO Alliance

Main Services

- Organizing BIO Asia–Taiwan International Conference and Exhibition
- Promoting the interests of our members
- Promoting international exchange and cooperation
- Promoting communication between government and industry
- Cultivating biotechnology industry talent
- Encouraging outstanding performance and innovation

Contact Information

Name:

Haiping Cheng

Position:

Marketing Manager

Tel:

+886-2-2783-6028 #17

Email:

haiping@taiwanbio.org.tw



<https://www.taitra.org.tw/en/>



Taiwan External Trade Development Council

Business Interests

- Customized Sourcing Service
- Trade Shows & Events
- Find Products & Suppliers
- Global Network

Main Services

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung as well as 59 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

Contact Information

Name:

Theresa Wang

Position:

Project Manager

Tel:

+886-2-2725-5200

Email:

theresawang@taitra.org.tw



Taiwan Stock Exchange

Business Interests

- Stock exchange

Main Services

The Taiwan Stock Exchange (the “TWSE”) started operations on February 9, 1962. The TWSE is not only responsible for operating and advancing the domestic securities market, but also provides comprehensive services to the stock market. The “TWSE” is dedicated to assisting companies to list on the capital market, raising funds and expanding their operational scale.

Contact Information

Name:

Kuo, Nai-Yu

Position:

Associate,
Foreign Listing Department

Tel:

+886-2-8101-3627

Email:

1210@twse.com.tw

GOVERNMENT



<https://nbrp.sinica.edu.tw/>



Biomedical Translation Research Center, Academia Sinica

Business Interests

- Collaborating with international bio-cluster/ bio-park, accelerator, incubation center, global pharma, government agency, biotech association, venture capital
- Space for startup related new drug discovery, smart healthcare & precision medicine
- Translational medical research cooperation
- Core facility support

Main Services

- Construct a Strong Biotech Ecosystem: Drives drug discovery and public health through innovation and collaboration.
- Incubate Startup Companies: One-stop R&D and commercialization services, plus training for future leaders.
- Support Innovative Biomedical Translation Research: Industry collaboration and funding accelerate biomedical discoveries into real-world applications.
- World-Class Core Facilities: Access to cutting-edge instruments and technical support speeds up research and clinical validation.

Contact Information

Name:

Rong-Jie (Jacky) Chen

Position:

Deputy COO

Tel:

+886-2-7750-5315

Email:

cet252@gate.sinica.edu.tw



<https://ccd.nat.gov.tw/biopharm>



Biotechnology and Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs

Business Interests

- R&D Collaboration
- Business Development
- Strategic Alliance
- Technology Transfer
- Financial Support
- Regulatory Affairs

Main Products / Service / Pipelines & Platforms

- The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) is the primary point of contact for Taiwan's biomedical industries.
- Established in 1996, BPIPO acts as the gateway to Taiwan's biomedical sector, serving as a vital link among various government units. Since 2001, it has been recognized as the one-stop shop for the biomedical industry, providing comprehensive business development support to companies around the globe.
- Each year, BPIPO supports over 100 companies in their growth, and in recent years, we have facilitated investments exceeding USD 1.5 billion annually into Taiwan's dynamic biomedical sector.

Contact Information

Name:

Chun-Yen (Richard) Chiang

Position:

Manager

Tel:

+886-2-2655-8135

Email:

cychiang@biopharm.org.tw



**Department of Academia-Industry
Collaboration and Science Park Affairs
National Science and Technology Council**

Business Interests

- Collaborative R&D
- Co-Development
- Strategic Alliance

Main Pipelines & Platforms

Enhance innovation and entrepreneurship for academic research:

- Foster university-driven deep tech ventures, connect corporates with global investors via Taiwan Tech Arena, and support startups through exhibitions and talent exchanges.

Support academia-industry relationship:

- Encourage businesses to collaborate with universities on applied research and strengthen cooperation.

Cultivate industrial talents:

- Offer Ph.D. students training in universities and internships.

Develop science parks:

- Strengthen science park policies, streamline regulations, improve investment reviews, and align talent development.

Contact Information

Name:
Albert Pan
Position:
Officer
Tel:
+886-2-2737-7571
Email:
albertpan0516@nstc.gov.tw



**Hsinchu Science Park Bureau,
National Science and Technology Council**

Business Interests

- Strategic Alliance

Main Services

- Wonderful investment incentives
 - Sound and stable infrastructure, water & power supply, telecommunications, and traffic facilities. Land is for lease only and standard fabs well-established for rent.
- Commodity and business taxes are free for self-use machines, equipment, raw materials, fuel, or semi-final products.
- Grants for Innovative industry-academia cooperation programs.
- Superior service quality and efficiency via one-stop services(e.g. company registration, talent cultivation, R&D grants application, factory and land leasing, etc.)

Contact Information

Name:
Yuki Chen
Position:
Officer
Tel:
+886-3-577-3311 #2228
Email:
yukichen23@sipa.gov.tw



Industrial Development Administration, Ministry of Economic Affairs

Business Interests

- International Collaboration

Main Mission

- The administration is in charge of the national industrial development tasks.
- Offer a full range of services according to industrial needs.
- Lead the industry of Taiwan to pursue innovation, upgrading, and enter-prise-transformation.
- Guide enterprises to strengthen their management system, increase productivity and enhance international competitiveness.
- Assist enterprises to face changes in the overall environment and provide policy subsidies.

Contact Information

Tel:
+886-2-2655-8135

Email:
services@biopharm.org.tw



Ministry of Agriculture

Business Interests

- Industry Sectors

Contact Information

Name:
Tsui-Feng Lee
Position:
Associate Technical Specialist
Tel:
+886-2-2312-4661
Email:
g7111491@mail.coa.gov.tw

Main Products / Services / Pipelines & Platforms

The Ministry of Agriculture is in charge of administration of agricultural, forestry, fisheries, and animal husbandry matters in Taiwan. Under the Ministry there are the Department of Planning, Department of Resources Sustainability, Department of Farmers' Guidance, Department of Animal Industry, Department of Animal Welfare, Department of Agricultural Science and Technology, Department of International Affairs, Department of Information Technology, Secretariat, Department of Personnel, Department of Government Ethics, Department of Accounting, Department of Statistics, and Department of Legal Affairs. Each department is divided into sections to meet operational needs.



<https://www.mohw.gov.tw/mp-2.html>



Ministry of Health and Welfare

Business Interests

- The MOHW's diversified responsibilities include health policy planning and promotion, prevention and control of disease, food safety, drug management, social insurance and welfare, relief and protective services.

Contact Information

Name:

Hsien-yang Lee

Position:

Researcher,
Office of Science and Technology

Tel:

+886-2-8590-7567

Email:

schsien-yanglee0641@mohw.gov.tw

Main Products / Services / Pipelines & Platforms

- The Ministry of Health and Welfare of the Republic of China (MOHW) is the Executive Yuan ministry responsible and the highest authority for the administration of the public health system, social welfare, affordable and universal health care, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan. The MOHW was originally established on 17 March 1971 as the Department of Health (DOH).
- The department was upgraded to Ministry of Health and Welfare on 23 July 2013 with the addition from the agencies in the Ministry of the Interior responsible for social welfare following restructuring of the Executive Yuan. The mission of MOHW is to promote the health and well-being of all Taiwan citizens.



<https://www.nstc.gov.tw/>



National Science and Technology Council

Business Interests

- IP/Tech feasibility and analysis for pharmaceuticals and medical devices
- Prototyping service for pharmaceuticals and medical devices
- Marketing analysis and regulatory compliance support for pharmaceuticals and medical devices
- Fund raising and accelerating commercialization for pharmaceuticals and medical devices

Contact Information

Tel:

+886-2-2652-2677

(Pharmaceuticals)

+886-3-658-8760 #2044

(Medical Device)

Email:

dcc@biip-dcc.org

(Pharmaceuticals)

pcchou@biip-mdcc.org

(Medical Device)

Main Services

The BioMed Commercialization Center (BMCC), funded by the National Science and Technology Council (NSTC), is to provide an integrated platform to overcome the bottleneck found in the development and commercialization of pharmaceuticals and medical devices for academia and industries.



<https://www.stsp.gov.tw/web/indexGroups?frontTarget=ENGLISH>



Southern Taiwan Science Park Bureau, National Science and Technology Council

Business Interests

- Collaborative R&D
- CDMO

Main Pipelines & Platforms

- Pharmaceutical Products
- Dental Products Combining the Integration of Software and Hardware
- Artificial Joints, Trauma, Spine and Other Orthopedic Products
- Minimally Invasive Medical Devices
- In Vitro Diagnostic Products
- Biomedical-Grade Collagen, Wound Care Dressings, Nano Dressings, Skin External Applications and Functional Cosmeceutical Products
- Biomedical Image Detection and Intelligent Image Monitoring

Contact Information

Name:
Lin,Yen-Ju
Position:
Specialist
Tel:
+886-6-5051001 #2160
Email:
yen928@stsp.gov.tw



<https://startupisland.tw/>



Startup Island TAIWAN

Business Interests

- Strategic Alliance
- Please reach out to us if you'd like to connect with startup ecosystem players in Taiwan

Contact Information

Name:
Evelyn Peng
Position:
Manager
Tel:
+886-2-3343-5456 #807
Email:
evelyn@startupisland.tw

Main Services

- Startup Island TAIWAN is the national startup brand jointly created by The National Development Council and the startup community.
- Facing out, we aim to demonstrate Taiwan's strong capabilities of innovation and entrepreneurship to the world through brand management. Facing in, we support large-scale startup activities and events as an innovative partner.
- Our services include:
 - Assistance connecting with overseas resources
 - Industry leaders driving business opportunities
 - Company training driving business opportunities
 - International tech exhibitions
 - Seizing opportunities for business



<https://www.biodriven.taipei/en/index.aspx>



Department of Economic Development, Taipei City Government

Business Interests

- Welcome Int'l bio companies to land in Taipei

Main Services

- Invest Taipei Office (ITO): One-Stop service to facilitate domestic and international investment and development in Taipei.
- Financial Support: Subsidies and Incentives for Taipei Industry project, Loan services.
- Brand Promotion: Taipei Biotech Awards.
- Matchmaking: Bio@Taipei website serves to disseminate industry news, promote policy resources, and showcase excellent biotech companies.
- Global Linkage: Lead Taipei enterprises to participate in international biotech exhibitions.
- Industrial Clusters: Taipei Bioinnovation Park, Neihu Technology Park, Beitou-Shilin Technology Park...etc.

Contact Information

Name:

Sonia Hsu

Position:

Researcher

Tel:

+886-2-2720-8889 #2090

Email:

ea-40177@gov.taipei

Note.

mon tue wed thu fri sat sun

/ /

Title